Mobility HCC and Mobility DC Joint Health

In a clinical study where both owners and veterinarians evaluated the dogs increased mobility was observed after 14 days taking Mobility DC.

Horse owners, trainers and riders have observed an increase in mobility after taking Mobility HCC for 14 days. Mobility HCC testimonials Mobility DC testimonials

Scientists in Germany recognized the need to develop a nutritional supplement to support joint health and mobility. Many of the supplements used to support joint health contain glucosamine and chondroitin sulphate where clinical studies are at best inconclusive regarding the effectiveness of these ingredients and  combinations. University of Sydney University of Bern

The US National Institute of Health funded an extensive study comprising 1,583 patients to evaluate these compounds. This study concluded “it seems prudent to tell our patients with symptomatic osteoarthritis of the knee that neither glucosamine nor chondroitin has been shown to be more efficacious than placebo for the treatment of knee pain”.

In addition, the American Academy of Orthopedic Surgeons states “Don’t use glucosamine and chondroitin to treat patients with symptomatic osteoarthritis of the knee – Both glucosamine and chondroitin sulphate do not provide relief for patients with symptomatic osteoarthritis of the knee”.

Many studies have shown that glucosamine and chondroitin sulphate do not help to relieve arthritic knees. People who take the supplements often report less pain or swelling of their joints. But people get similar results if they take a placebo—a “sugar pill” with no active ingredients. Pain relieving drugs, such as acetaminophen and ibuprofen, help a lot more.

Hyaluronic acid has long been recognized as a vital component of joint fluid, providing cushioning and lubrication for all joints. The safety and effectiveness of hyaluronic acid in treating degenerative joint disease and osteoarthritis of the knee, and the associated pain, has been established in extensive clinical studies.

Hyaluronic acid for direct injection into the knee has been approved by numerous regulatory authorities including Europe, USA, Japan, Canada and Australia. Hyaluronic acid and Osteoarthritis of the knee

Until recently the use and effectiveness of orally administered hyaluronic acid has been limited, the reasons being:

- the concentration of hyaluronic acid in the products was insufficient to achieve clinical significance

- the molecular size of the hyaluronic acid was inappropriate for absorption through the gastrointestinal tract

Extensive research was conducted in Germany to determine the optimal formulation and molecular size of hyaluronic acid to be orally absorbed. Based on this research Mobility HCC and Mobility DC were developed.

A study was conducted on 29 dogs with assessments from both owners and veterinarians. This controlled study demonstrated effectiveness and safety as no adverse events were reported (Learn more: Dog Study)

This approach to the administration of hyaluronic acid has numerous advantages compared with the injectable form including:

- is not limited to the injected joint

- treats all joints with degenerative disease

- less intrusive with the associated reduced risks

• Infection
• Damage to surface of articular cartilage

- less expensive

- higher concentrations of hyaluronic acid can be administered

ABC journalist Connie Chung documentary The Miracle of Hyaluronic Acid